A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial)

Objective We aimed to compare angiographic and clinical outcomes after the implantation of everolimus‐eluting (EES) and sirolimus‐eluting (SES) stents in patients with diabetes. Background There are limited data on long‐term outcome after EES vs SES implantation in diabetic patients. Methods We randomized 213 patients with diabetes and coronary artery disease to EES (n = 108) or SES (n = 105) implantation. Angiographic follow‐up was performed 10 months after the index procedure and all patients were followed clinically for 4 years. The primary endpoint was angiographic in‐stent late luminal loss at 10‐month follow‐up. Secondary endpoints included angiographic restenosis rate, the need for target lesion revascularization (TLR) and major adverse cardiac events (MACE; defined as cardiac death, myocardial infarction, definite stent thrombosis, or TLR) at 4‐year follow‐up. Results At 10‐month angiographic follow‐up, in‐stent late lumen loss was 0.20 ± 0.53 mm and 0.11 ± 0.49 mm (P = 0.28), and angiographic restenosis rate was 3.8% and 5.2% (P = 0.72) in the EES and SES groups, respectively. At 4‐year clinical follow‐up, MACE had occurred in 22 (20.4%) patients in the EES group and 25 (23.8%) patients in SES group (HR 0.84, 95% CI 0.47–1.49; P = 0.55), with TLR performed in 6 (5.6%) and 10 (9.5%) patients in the two groups (HR 0.57, 95% CI 0.21‐1‐58; P = 0.28). Conclusion EES and SES had comparable 10‐month angiographic and 4‐year clinical outcomes in patients with diabetes mellitus and coronary artery disease. © 2015 Wiley Periodicals, Inc.